Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani

Advances in covalent drug discovery

A chemoproteomic platform for reactive fragment profiling against the deubiquitinases

Structure-guided discovery of potent human NMT inhibitors a, Structures

Compounds 1a-c and 2a-b bind in the Plasmodium NMT peptide binding

Plasmodium falciparum NMT substrates are involved in a variety of

ACS Infectious Diseases

Key needs to accelerate Cryptosporidium drug development.

NMT inhibition results in loss of the inner membrane complex and